Transperineal vs. Transrectal MRI-targeted Prostate Biopsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04815876|
Recruitment Status : Recruiting
First Posted : March 25, 2021
Last Update Posted : March 17, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer.
This randomized controlled trial will be the first prospective study to evaluate in-office transperineal MRI targeted prostate biopsy.
The investigators hypothesize that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer.
|Condition or disease||Intervention/treatment||Phase|
|Infection||Procedure: Transperineal MRI-guided prostate biopsy Procedure: Transrectal MRI-guided prostate biopsy Drug: Antibiotic (prophylaxis)||Not Applicable|
Prostate cancer is the most commonly diagnosed malignancy in U.S. men. There are approximately 1 million prostate biopsy performed annually in the U.S. Almost all biopsies are performed as an office based procedure in under 15 minutes. The precision of biopsy has improved over the last decade with the introduction of MRI guidance/targeting of suspicious lesions within the prostate.
However, significant limitations remain with this approach, including a significantly increasing risk of post-biopsy infection. This arises because more than 97% of all prostate biopsy are performed via a transrectal approach that introduces rectal bacteria with each pass of the biopsy needle into the sterile urinary tract. The current risk of post-transrectal biopsy infection, even with antimicrobial prophylaxis, is high at approximately 7% overall with 3% (30,000 men) requiring hospitalization annually.
Transperineal biopsy is an alternate approach that eliminates the direct introduction of bacteria from the rectum to the prostate. This approach, which is perfomed without antimicrobial prophylaxis, instead passes the biopsy needle through the perineal skin and pelvic floor.
Transperineal biopsy has not been widely adopted for several reasons. Historically, it has been considered too painful for patients in the clinic and thus was traditionally performed under general anesthesia. The added time, inconvenience and cost has limited its national adoptance. Second, when transrectal biopsy was initially adopted over 40 years ago, antibiotic resistance of rectal flora was not a challenge.
Beyond the potential for in-office transperineal biopsy to significantly reduce or eliminate biopsy infections, transperineal biopsy may also improve cancer detection: studies of transperineal biopsy (performed under general anesthesia) demonstrate higher detection rates for prostate cancer, particularly for anterior zone tumors, compared to transrectal biopsy. This is notable, as anterior tumors are difficult to sample with transrectal. Anterior tumors are also twice as likely to occur in African American men. In fact, our research demonstrates that some of the outcomes disparities in African American men may stem from an underdiagnosis of anterior prostate cancers.
Although transrectal biopsy is used widely, it is associated with a significant and increasing risk of biopsy infections due to growing antibiotic resistance, highlighting the urgent need for a safer alternative approach to prostate biopsy. The study investigators have refined a transperineal approach under local anesthesia with MRI-targeting/guidance without the need for antibiotic prophylaxis. The investigators hypothesize that transperineal MRI targeted biopsy will: (1) largely eliminate post-biopsy infections and costly hospitalizations for urosepsis; (2) be performed in the office with similar discomfort and non-infectious complications compared to transrectal MRI targeted biopsy; and (3) have significantly better detection of prostate cancer.
This multi-center randomized controlled trial will be conducted to evaluate in-office transperineal MRI targeted vs. transrectal MRI targeted biopsy, the current gold standard. This has transformative impact to change current standard of practice.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1302 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Men enrolled in this prospective, randomized trial will be randomized in a 1:1 ratio to receive either transperineal MRI-targeted or transrectal MRI-targeted prostate biopsy.|
|Masking:||Single (Outcomes Assessor)|
|Masking Description:||Radiologists assessing MRI results are blinded to treatment assignment. Pathologists assessing biopsy results are blinded to treatment assignment.|
|Official Title:||Randomized Trial Comparing Transperineal vs. Transrectal MRI-targeted Prostate Biopsy|
|Actual Study Start Date :||June 24, 2021|
|Estimated Primary Completion Date :||February 1, 2024|
|Estimated Study Completion Date :||April 30, 2025|
Active Comparator: Transrectal
Patients will receive a transrectal MRI-guided prostate biopsy.
Procedure: Transrectal MRI-guided prostate biopsy
Transrectal prostate biopsy is currently the most popular approach to evaluate a positive screening test for prostate cancer.
Drug: Antibiotic (prophylaxis)
For men undergoing transrectal biopsy, antibiotic prophylaxis will be administered in accordance with guidelines from the American Urological Association (AUA).
No antibiotic prophylaxis will be administered for men undergoing transperineal biopsy.
Active Comparator: Transperineal
Patients will receive a transperineal MRI-guided prostate biopsy.
Procedure: Transperineal MRI-guided prostate biopsy
Transperineal prostate biopsy will be performed under local anesthesia in the office. This approach avoids transrectal needle tracking.
- Change in infection adverse events, as measured on TRUS-BxQ [ Time Frame: At initiation of biopsy, immediately following biopsy, 7 days post-biopsy ]TRUS-BxQ is a validated biopsy questionnaire that measures adverse events that have occurred due to infection. Patient questionnaire consists of Yes/No questions about infection complications and duration of infection.
- Change in patient-reported pain and discomfort, as measured on a 0-10 Likert scale [ Time Frame: Immediately following biopsy, 7 days post-biopsy ]Pain and discomfort will be scored on a 0-10 Likert scale. 0 indicates no pain/discomfort and high scores indicate greater pain/discomfort.
- Change in patient-reported anxiety, as measured on a 0-10 Likert scale [ Time Frame: Immediately following biopsy, 7 days post-biopsy ]Anxiety will be scored on a 0-10 Likert scale. 0 indicates no anxiety and high scores indicate greater anxiety.
- Detection of clinically significant disease as measured by Gleason Grade Group ≥ 2 [ Time Frame: 7 days post-biopsy ]
Gleason Grade Group is a prostate cancer grading system released by the International Society of Urological Pathology (ISUP). Grade Group 1 indicates Low/Very Low Risk, Grade Group 2 indicates Intermediate (Favorable) Risk, Grade Group 3 indicates Intermediate (Unfavorable) Risk, and Grade Groups 4 and 5 indicate High/Very High Risk.
Prostate cancer grade will be categorized into insignificant (Gleason Grade Group 1) and clinically significant (Grade Group ≥ 2).
- Change in adverse events, as measured on TRUS-BxQ [ Time Frame: At initiation of biopsy, immediately following biopsy, 7 days post-biopsy ]TRUS-BxQ is a validated biopsy questionnaire that measures adverse events that have occurred, such as hospital re-admissions, aborted procedures due to discomfort, hematuria, urinary retention, hematospermia, and/or hematochezia. Patient questionnaire consists of Yes/No questions about general complications and duration of adverse events.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Active surveillance cohort: History of Grade Group 1 prostate cancer, first diagnosed ≤24 months prior to date of planned confirmatory biopsy and diagnostic biopsy was preceded by a multiparametric MRI of the prostate
- Prior negative cohort: Clinical concern for the presence of prostate cancer as determined by the treating urologist and prior negative prostate biopsy performed ≤36 months prior to date of planned biopsy
- Willingness to sign informed consent and adhere to the study protocol
- Acute prostatitis within the last 6 months
- Current non-urologic bacterial infection requiring active treatment with antibiotics
- Unfit to undergo prostate biopsy under local anesthesia
- Prior definitive therapy for prostate cancer, such as radiation therapy or partial gland ablation
- Contraindication to prostate MRI (claustrophobia, pacemaker, chronic kidney disease)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04815876
|Contact: Jim Hu, MD MPHfirstname.lastname@example.org|
|United States, Connecticut|
|University of Connecticut||Recruiting|
|Farmington, Connecticut, United States, 06030|
|Contact: Katarzyna Nastri email@example.com|
|Principal Investigator: Benjamin Ristau, MD|
|United States, District of Columbia|
|Washington, District of Columbia, United States, 20007|
|Contact: Keith Kowalczyk, MD Keith.Kowalczyk@medstar.net|
|Principal Investigator: Keith Kowalczyk, MD|
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Contact: Margarita "Sachi" Mana-ay, MSN, MPH 312-695-8146 Margarita.Manafirstname.lastname@example.org|
|Principal Investigator: Edward M Schaeffer, MD PhD|
|United States, Maryland|
|Johns Hopkins University||Recruiting|
|Baltimore, Maryland, United States, 21287|
|Contact: Rana Harb, MS 410-502-5500 email@example.com|
|Principal Investigator: Mohamad E Allaf, MD|
|United States, Michigan|
|University of Michigan||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Contact: Sharada Lanka, MS firstname.lastname@example.org|
|Contact: Jeffrey S Montgomery, MD 734-647-8903 email@example.com|
|United States, New York|
|NewYork-Presbyterian Brooklyn Methodist Hospital||Not yet recruiting|
|Brooklyn, New York, United States, 11217|
|Contact: Danielle Hayden 646-962-9343 firstname.lastname@example.org|
|Principal Investigator: John Graham, MD|
|Flushing, New York, United States, 11355|
|Contact: Danielle Hayden 646-962-9343 email@example.com|
|Principal Investigator: David Green, MD|
|Principal Investigator: Gerald Wang, MD|
|Memorial Sloan Kettering Cancer Center||Recruiting|
|New York, New York, United States, 10065|
|Contact: Marlena McGill 646-227-2231 firstname.lastname@example.org|
|Principal Investigator: Behfar Ehdaie, MD MPH|
|United States, Ohio|
|University Hospitals Cleveland Medical Center||Recruiting|
|Cleveland, Ohio, United States, 44106|
|Contact: Rosemary Brewka, MS email@example.com|
|Principal Investigator: Jonathan Shoag, MD|
|United States, Pennsylvania|
|Einstein Healthcare Network||Recruiting|
|Elkins Park, Pennsylvania, United States, 19027|
|Contact: Serge Ginzburg, MD 215-663-6067 firstname.lastname@example.org|
|Principal Investigator: Serge Ginzburg, MD|
|Fox Chase Cancer Center||Not yet recruiting|
|Philadelphia, Pennsylvania, United States, 19111|
|Contact: Victoria Sabella 215-728-3122 email@example.com|
|Principal Investigator: Andres Correa, MD|
|Principal Investigator:||Jim C Hu, MD MPH||Weill Cornell Medicine, NewYork-Presbyterian|
|Responsible Party:||Weill Medical College of Cornell University|
|Other Study ID Numbers:||
CER-2019C2-17372 ( Other Identifier: Patient-Centered Outcomes Research Institute )
18-02-365-PCORI ( Other Identifier: Biomedical Research Alliance of New York (BRANY) )
|First Posted:||March 25, 2021 Key Record Dates|
|Last Update Posted:||March 17, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Product Manufactured in and Exported from the U.S.:||No|